10X Genomics Inc
TXG13.925USD
+0.825+6.30%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
1.73BCap. mercado
PérdidaP/E TTM
Más Datos de 10X Genomics Inc Compañía
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for analyzing biological systems. Its Chromium platform includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, and others.
Información de la empresa
Símbolo de cotizaciónTXG
Nombre de la empresa10X Genomics Inc
Fecha de salida a bolsaSep 12, 2019
Director ejecutivoMr. Serge Wilson Saxonov, Ph.D.
Número de empleados1306
Tipo de seguridadOrdinary Share
Fin del año fiscalSep 12
Dirección6230 Stoneridge Mall Road
CiudadPLEASANTON
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal94588
Teléfono19254017300
Sitio Webhttps://www.10xgenomics.com/
Símbolo de cotizaciónTXG
Fecha de salida a bolsaSep 12, 2019
Director ejecutivoMr. Serge Wilson Saxonov, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Serge Wilson Saxonov, Ph.D.
Mr. Serge Wilson Saxonov, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
1.07M
-0.09%
Dr. John R. Stuelpnagel
Dr. John R. Stuelpnagel
Independent Chairman of the Board
Independent Chairman of the Board
369.61K
+4.34%
Whitaker (Eric S)
Whitaker (Eric S)
Chief Legal Officer
Chief Legal Officer
202.20K
+29.09%
Mr. Sridhar (Sri) Kosaraju
Mr. Sridhar (Sri) Kosaraju
Independent Director
Independent Director
59.45K
+34.83%
Dr. Benjamin J. Hindson, Ph.D.
Dr. Benjamin J. Hindson, Ph.D.
President, Co-Founder, Chief Scientific Officer, Director
President, Co-Founder, Chief Scientific Officer, Director
52.17K
-12.55%
Ms. Kimberly J. (Kim) Popovits
Ms. Kimberly J. (Kim) Popovits
Independent Director
Independent Director
28.62K
+115.82%
Dr. Shehnaaz Suliman, M.D.
Dr. Shehnaaz Suliman, M.D.
Independent Director
Independent Director
28.62K
+115.82%
Mr. Adam S. Taich
Mr. Adam S. Taich
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Alan V. Mateo
Mr. Alan V. Mateo
Independent Director
Independent Director
--
--
Dr. Sarah A. Teichmann
Dr. Sarah A. Teichmann
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Serge Wilson Saxonov, Ph.D.
Mr. Serge Wilson Saxonov, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
1.07M
-0.09%
Dr. John R. Stuelpnagel
Dr. John R. Stuelpnagel
Independent Chairman of the Board
Independent Chairman of the Board
369.61K
+4.34%
Whitaker (Eric S)
Whitaker (Eric S)
Chief Legal Officer
Chief Legal Officer
202.20K
+29.09%
Mr. Sridhar (Sri) Kosaraju
Mr. Sridhar (Sri) Kosaraju
Independent Director
Independent Director
59.45K
+34.83%
Dr. Benjamin J. Hindson, Ph.D.
Dr. Benjamin J. Hindson, Ph.D.
President, Co-Founder, Chief Scientific Officer, Director
President, Co-Founder, Chief Scientific Officer, Director
52.17K
-12.55%
Ms. Kimberly J. (Kim) Popovits
Ms. Kimberly J. (Kim) Popovits
Independent Director
Independent Director
28.62K
+115.82%
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Consumables
115.36M
74.48%
Products and services revenue
17.06M
11.01%
Instruments
14.81M
9.57%
Services
7.65M
4.94%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
86.82M
56.05%
Europe, the Middle East and Africa
31.89M
20.59%
China
16.88M
10.90%
Asia Pacific
15.54M
10.03%
Americas
3.75M
2.42%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Consumables
115.36M
74.48%
Products and services revenue
17.06M
11.01%
Instruments
14.81M
9.57%
Services
7.65M
4.94%
Estadísticas de accionistas
Actualizado: sáb., 16 de ago
Actualizado: sáb., 16 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
ARK Investment Management LLC
12.14%
The Vanguard Group, Inc.
10.85%
Fidelity Management & Research Company LLC
6.68%
BlackRock Institutional Trust Company, N.A.
6.63%
Sumitomo Mitsui Trust Bank, Limited
5.26%
Otro
58.44%
Accionistas
Accionistas
Proporción
ARK Investment Management LLC
12.14%
The Vanguard Group, Inc.
10.85%
Fidelity Management & Research Company LLC
6.68%
BlackRock Institutional Trust Company, N.A.
6.63%
Sumitomo Mitsui Trust Bank, Limited
5.26%
Otro
58.44%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
53.70%
Investment Advisor/Hedge Fund
22.23%
Hedge Fund
13.91%
Bank and Trust
6.38%
Research Firm
4.81%
Venture Capital
2.31%
Individual Investor
1.87%
Pension Fund
0.63%
Family Office
0.51%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
669
120.42M
108.39%
-15.20M
2025Q1
687
115.67M
104.27%
-8.84M
2024Q4
689
107.08M
98.92%
-12.41M
2024Q3
682
106.90M
100.39%
-9.08M
2024Q2
691
105.36M
99.70%
-5.09M
2024Q1
762
106.36M
101.17%
-3.12M
2023Q4
817
100.80M
96.01%
-9.73M
2023Q3
835
96.86M
93.80%
-12.55M
2023Q2
857
94.98M
96.77%
-15.37M
2023Q1
864
95.62M
97.55%
-9.91M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
ARK Investment Management LLC
12.85M
11.56%
+901.66K
+7.55%
Mar 31, 2025
The Vanguard Group, Inc.
11.09M
9.99%
+184.54K
+1.69%
Mar 31, 2025
Fidelity Management & Research Company LLC
8.58M
7.72%
-2.75M
-24.30%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
5.41M
4.87%
-108.37K
-1.96%
Mar 31, 2025
Sumitomo Mitsui Trust Bank, Limited
5.36M
4.83%
+5.36M
--
Mar 31, 2025
BofA Global Research (US)
2.56M
2.3%
+2.03M
+386.97%
Mar 31, 2025
Millennium Management LLC
5.53M
4.98%
+156.13K
+2.90%
Apr 01, 2025
Two Sigma Investments, LP
3.17M
2.85%
+614.32K
+24.04%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.88M
1.69%
+62.79K
+3.46%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: mié., 6 de ago
Actualizado: mié., 6 de ago
Nombre
Proporción
ARK Genomic Revolution ETF
3.68%
WisdomTree BioRevolution Fund
1.76%
Global X Genomics & Biotechnology ETF
1.69%
ARK Innovation ETF
1.63%
Invesco NASDAQ Future Gen 200 ETF
0.55%
First Trust Nasdaq Lux Digi Health Solutions ETF
0.41%
Vanguard US Quality Factor ETF
0.15%
ProShares Ultra Nasdaq Biotechnology
0.14%
Invesco Nasdaq Biotechnology ETF
0.14%
iShares Biotechnology ETF
0.14%
Ver más
ARK Genomic Revolution ETF
Proporción3.68%
WisdomTree BioRevolution Fund
Proporción1.76%
Global X Genomics & Biotechnology ETF
Proporción1.69%
ARK Innovation ETF
Proporción1.63%
Invesco NASDAQ Future Gen 200 ETF
Proporción0.55%
First Trust Nasdaq Lux Digi Health Solutions ETF
Proporción0.41%
Vanguard US Quality Factor ETF
Proporción0.15%
ProShares Ultra Nasdaq Biotechnology
Proporción0.14%
Invesco Nasdaq Biotechnology ETF
Proporción0.14%
iShares Biotechnology ETF
Proporción0.14%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
